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 Abstract 
Intrachromosomal amplification of chromosome 21 is a heterogeneous chromosomal 
rearrangement occurring in 2% of childhood precursor B-cell acute lymphoblastic leukemia. There 
are no cell lines with iAMP21 and these abnormalities are too complex to faithfully engineer in 
animal models. As a resource for future functional and pre-clinical studies, we have created 
xenografts from intrachromosomal amplification of chromosome 21 leukemia patient blasts and 
characterised them by in-vivo and ex-vivo luminescent imaging, FLOW immunophenotyping, and 
histological and ultrastructural analysis of bone marrow and the central nervous system. 
Investigation of up to three generations of xenografts revealed phenotypic evolution, branching 
genomic architecture and, compared with other B-cell acute lymphoblastic leukemia genetic 
subtypes, greater clonal diversity of leukemia initiating cells. In support of intrachromosomal 
amplification of chromosome 21 as a primary genetic abnormality, it was always retained through 
generations of xenografts, although we also observed the first example of structural evolution of this 
rearrangement. Clonal segregation in xenografts revealed convergent evolution of different 
secondary genomic abnormalities implicating several known tumour suppressor genes and a region, 
containing the B-cell adaptor, PIK3AP1, and nuclear receptor co-repressor, LCOR, in the progression 
of B-ALL. Tracking of mutations in patients and derived xenografts provided evidence for co-
operation between abnormalities activating the RAS pathway in B-ALL and for their aggressive clonal 
expansion in the xeno-environment. Bi-allelic loss of the CDKN2A/B locus was recurrently 
maintained or emergent in xenografts and also strongly selected as RNA sequencing demonstrated a 
complete absence of reads for genes associated with the deletions. 
 
 
 
 
 Introduction. 
Xenograft models of leukemia have been used to address a number of important fundamental and 
translational research questions relating to: the nature of leukemia stem cells, clonal evolution and 
experimental therapies.(1-8) Limiting dilution studies have demonstrated that leukemia initiating 
cells (LIC) are common, while fluorescence in situ hybridisation (FISH), genomic arrays, analysis of 
Ig/TCR rearrangements, immunophenotype and drug response have suggested that the disease can 
be propagated through multiple generations of mice with high fidelity.  
Intrachromosomal amplification of chromosome 21 (iAMP21) is an intriguing cytogenetic 
abnormality, defining a specific subgroup of approximately 2% of childhood precursor B-cell acute 
lymphoblastic leukemia (B-ALL). Chromosome 21 genomic profiles, although highly variable, always 
involve amplifications, flanked by regions of normal copy number or deletion(9, 10). We have shown 
that the oncogenic potential of chromosome 21 is optimised through a combination of catastrophic 
sequence reorganisation, driven by chromothripsis, deletion and amplification, resulting from 
dicentric chromosome formation, breakage-fusion-bridge (BFB) cycles and whole chromosome arm 
duplications.(11) This mechanism has the potential to produce a near infinite number of alternative 
derivative chromosomes 21. The structure of the iAMP21 chromosome is stabilised by telomere 
acquisition or duplication, while a combination of protected amplified genes are postulated to 
confer an overall growth advantage, leading to the development of ALL. Several lines of evidence 
indicate that iAMP21 is a stable, primary genetic change: 1) among 530 patients, iAMP21 was 
reported as a sub-clonal abnormality in only a single case,(12) 2) the iAMP21 chromosome 
morphology remains consistent between cells in the same patient, 3) the same chromosome 
structure is observed at diagnosis and relapse.(9) A range of specific secondary genetic 
abnormalities: CRLF2 activating rearrangements, X chromosome gain, deletions of RB1, ETV6, the 
long arm of chromosome 7 (7q) and 11q, and mutations of the RAS pathway frequently co-occur 
with iAMP21.(9, 12, 13)  
 This distinct iAMP21-ALL subgroup is clinically defined by older age (median 9 years), low white 
blood cell counts (WBC) and a high risk of relapse on standard therap.(14-16) Intensive therapy 
significantly reduced the relapse risk(17, 18) but associated morbidity highlights an urgent need for 
less toxic regimens. Development of rational targeted therapies requires understanding of the 
mechanism by which these rearrangements initiate leukemia. However the requisite tools for 
functional studies are lacking because no iAMP21-ALL cell lines exist and the complex nature of the 
abnormalities exclude their reproduction in engineered animal models. To address this shortfall, we 
transplanted primary leukemia cells from five iAMP21-ALL patients into NOD/LtSz-scid IL2Rγ null 
(NSG) mice. In-vivo luminescent imaging, to track the physical development of ALL, was used to 
assess these xenografts as potential models for functional and pre-clinical studies. In addition, we 
have characterised the disease morphology at the microscopic and ultrastructural level and, as a first 
application, have performed extensive genomic analysis to investigate clonal heterogeneity of 
iAMP21-ALL, from which some intriguing findings have emerged. 
Methods. 
Patients.  
Viable cells from children diagnosed with iAMP21-ALL, as previously defined,(19) were provided by 
the Bloodwise Childhood Leukemia Cell Bank. Ethical approval was obtained for all patients and 
informed consent was granted in accordance with the Declaration of Helsinki. Karyotypes and 
demographic details of patients used to generate xenografts or as controls for histological analysis 
are presented in Supplementary Tables 1 - 3.  
Xenografts and isolation of leukemia cells.  
Primografts were created by intrafemoral injection of patient cells into NSG mice, as previously 
described.(1) Between 2x10
4
 and 2x10
6
 primograft bone marrow or spleen cells from each mouse 
were used in the same procedure to create 2° and 3° xenografts (Supplementary Table 4). 
 Xenografts were culled at end stage disease as defined in the online supplementary methods. Bone 
marrow cells flushed from femurs and disaggregated spleens were passed through 40µm cell 
strainers. Leukaemic cells used for all experimental work were purified from spleen preparations by 
separation over Ficol-Paque [density 1.077] (G.E. Health Care, Buckinghamshire, UK). Proportions of 
human and mouse cells and immunophenotypes of the human leukemia fractions were determined 
by flow cytometry as described in the online supplementary methods.  
Lentiviral transduction, in-vitro culture and in-vitro, in-vivo and ex-vivo imaging of xenograft cells. 
Detailed procedures are provided in the online supplementary methods.  
Histopathology and Transmission Electron Microscopy (TEM).  
Detailed procedures are provided in the online supplementary methods.  
SNP6.0 arrays.  
DNA extraction and SNP6.0 array hybridisation and analysis was performed, as previously 
described.(13) To define regions of chromosome 21 copy number (CN) evolution, SNP CN values 
were subtracted between 2° xenografts F7897RN and F7897LN. CN abnormalities (CNA) in 
immunoglobulin or T-cell receptor regions, those not involving coding gene regions, present in 
patient remission sample or reported in the Toronto Database of Genomic Variants, were not 
reported. Genomic positions are for Hg19.  
Fluorescence in situ hybridisation (FISH) and Multiplex Ligation-dependent Probe Amplification 
(MLPA).  
Dual colour FISH on 100-200 interphase cells was performed using fluorescently labelled BAC probes 
hybridising to the RUNX1 (RP11-773I18) and APP (RP11-66H5 and RP11-15D13) genomic regions or 
commercially available probes to the CDKN2A/B genomic region and chromosome 9 centromere 
 (CytoCell, Cambridge UK), as previously described.(20) MLPA was performed using the SALSA MLPA 
335 kit (MRC-Holland, The Netherlands), as previously described.(21) 
Analysis of RAS pathway mutations and RNA sequencing. 
Detailed procedures are provided in the online supplementary methods.  
Results. 
Development of iAMP21-ALL xenografts and characterisation by in-vivo and ex-vivo imaging.  
Of six primary and two relapsed cases of iAMP21-ALL transplanted into femurs of NSG mice, five, 
including one relapse case, developed ALL derived from the human cells, in one or more animals 
(Supplementary Table 1). Mean time to development of end stage disease in primografts was 30 
weeks and splenomegaly was seen in all engrafted animals. 2° and 3° xenografts were established in 
three and one cases respectively, and all were assigned unique identifiers indicating passage number 
and patient of origin, for example 2°3e was one of several secondary xenografts derived from 
patient 3. Xenograft leukemia cells constituted between 40-92% of bone marrow and 23-53% and 
79-99% of crude and purified spleen samples respectively (Supplementary Table 4).  Essentially all 
human cells isolated from xenografts expressed the B-cell markers CD19 and CD10 but analysis of 
CD34 and CD38 demonstrated considerable phenotypic divergence between mice (supplementary 
table 5 and supplementary figure 1).  
To investigate their potential for use in in-vivo and in-vitro functional studies, we transduced 
xenograft stocks from four iAMP21-ALL patients with the pSLIEW lentivirus vector that expresses 
luciferase and EGFP.(22) Three days after transduction, a total of 3x10
6
 cells from each patient were 
transplanted by intra-femoral injection into two NSG mice each, here identified by patient number 
followed by a
SLIEW
 or b
SLIEW
. Less than 1% of transduced cells were GFP positive by FACS analysis at 
this time point (supplementary Figure 2) or by fluorescence microscopy after one week culture on 
MS-5 feeder layers (data not shown),  nevertheless, by 2-4 weeks following transplant, luminescent 
 signals, clearly localised to the injected femurs, were seen on whole body imaging of all mice. 
Leukemia spread to other bones and organs with noticeable variation in the strength of signal at 
some sites (Supplementary Figure 3). This variation was highlighted by measurement of luminescent 
signals from organs post mortem and by analysis of the relationship between signal development at 
different sites over time (Figures 1A, 1B and table 1). In spleen signal variation was shown to relate 
to the proportion of infiltrating blast cells that expressed EGFP rather than to overall tumour load 
(Figures 1C, Table 1 and Supplementary Table 4). Serial 3D reconstruction of one xenograft showed 
dramatic increases in signals from the spleen and head between weeks 11-15 (Figure 1D).  
Morphology and ultrastructure of bone marrow and CNS reveals patient specific heterogeneity, 
including evidence for systemic bone marrow niche destruction.  
To investigate bone marrow morphology and CNS involvement in the iAMP21-ALL models, we 
examined sections through tibias, sternums and heads of the mice engrafted with SLIEW transduced 
cells. H&E stained control NSG bone marrow resembled that of a wild type mouse(23) and was 
negative for anti-human CD19, CD45 and Ki-67 staining (Figure 2A and Supplementary Figure 4). In 
xenografts, two types of morphology were seen, both of which differed from controls; type A, which 
closely resembled that of iAMP21-ALL patient trephines (Figures 2B, 2G, Supplementary Figures 4 
and 5 and Supplementary table 2) and type B, which although abnormal, clearly differed from the 
patient trephines (Figures 2C, 2G and Supplementary Figure 4). Cells in type A but not type B 
sections were actively cycling and of human origin as indicated by staining with anti-human Ki67, 
CD19 and CD45 antibodies (Figures 2D and Supplementary Figure 4). Individual sections presented 
with either type A or B morphology only with the exception of one sternum segment where both 
types co-existed (Figure 2D). There was relatively sharp demarcation between the A and B type 
areas, suggesting that the iAMP21 ALL cells were organized into massive clumps that didn’t easily 
diffuse within the lumen. 
 From different tibia or forelimb bones of each mouse, we performed TEM of decalcified sections. 
Xenograft ultrastructure always differed from wild type controls and, as with bright field microscopy, 
two distinct categories could be identified (Figure 2E and Supplementary Figure 6). The first was 
termed viable leukemia (VL), as mitotic figures were present and cells appeared normal, although 
homogeneous by comparison with controls. There were more connections and less extracellular 
space between cells in preparations from 4a/b
SLIEW
 compared with controls and 1a/b
SLIEW
. The second 
category, equivalent to histological type B, was termed apoptotic (AP), as no mitotic figures were 
present and cells were depleted in number with classical signs of apoptosis, in the form of 
condensed chromatin localised to the periphery of the nucleus.(24)  
We also examined sections through the skulls and CNS of seven of the eight xenografts (Figures 2F 
and Supplementary Figure 7), revealing calvaria in all cases, packed with homogeneously stained 
cells resembling the A type morphology of tibia sections. CNS involvement ranged from small foci of 
leukemia cells to heavy meningeal infiltration, extending into the choroid plexus in one case. 
Comparison of CNS histological grades for each xenograft with bone marrow histopathology and 
TEM data (Table 2) showed heavy CNS involvement only in 1a/b
SLIEW 
and 4a/b
SLIEW
, correlating with 
fibia marrow histological type A and TEM type VL. We infer the proportion of transduced cells 
infiltrating the CNS varied between mice because luminescent signals from the head failed to 
correlate with histological grade (Table 2).  
To investigate the relative incidence of the morphological types we examined H&E and anti CD19 
stained bone marrow sections from 13 additional xenografts derived from seven B-ALL patients 
(Supplementary Tables 3 and 6). Among these cases, type B morphology was seen in two 
primografts, one derived from a relapsed iAMP21-ALL patient and the second from a case with high 
hyperdiploid ALL, areas of A type morphology were also seen in both (Supplementary Figure 8). 
Other xenografts displayed A type morphology either exclusively (Supplementary Figure 9) or 
infiltrating apparently normal mouse bone marrow (Supplementary Figure 10). Interestingly these 
 latter cases supported our initial observation that the ALL cells may grow in clumps because 
CD19+ve cells formed distinct clusters.   
Segregation of CNA in xenografts implicates known and novel genes in the progression of iAMP21-
ALL. 
We used SNP6.0 array profiles to evaluate the genomic stability of iAMP21-ALL in 21 xenografts from 
five patients. Presentation and remission samples were available for all except patient 4. A core of 3-
16 concordant CNA, involving coding gene regions, were clonal at presentation and retained in all 
xenografts (Supplementary Table 7). The existence of competing sub-clones and branching genomic 
evolution was demonstrated by discordant CNA, which occurred at a rate of between 4 and 12 
(Figure 3 and Supplementary Table 7). Clonal trisomies or copy number neutral loss of 
heterozygosity (CN-LOH), present in each patient sample, were lost after transplant, while deletions 
and amplifications were typically sub-clonal and either lost or increased in level or newly emergent 
as sub-clones in xenografts. Exceptionally in xenografts of patient 1, a sharp transition in genomic 
architecture, involving clonal gain of CNA of three chromosomes, occurred. Chromosome 21 profiles 
usually remained unchanged across samples (Supplementary Figure 11), but interestingly in cells 
from patient 1, we observed structural evolution of the iAMP21 chromosome, involving a small 
region of copy number gain and nine distinct regions of loss of one or two copies (Figure 3A and 
Supplementary Table 8). Importantly the additional deletions did not affect two regions predicted to 
contain critical oncogenes(11) but did re-define the proximal boundary of the region of highest level 
of amplification(9) from 21:32,813,553-37 to 21:33,949,423. By FISH, we confirmed that the RUNX1 
and APP gene regions were maintained at the same level of amplification and reduced in copy 
number from three to one, respectively. Additional rearrangements included bi-allelic deletion of 
the short arm of chromosome 9 (9p), resulting in homozygous loss of CDKN2A/B, as confirmed by 
MLPA (Supplementary Table 9), and mono-allelic deletion of 3p, involving the CMTM genes 6-8. 
SNP6.0 array and FISH provided no evidence of these CNA prior to their emergence in 2°1a. 
 However, as previously reported, two reads in whole genome sequencing data were consistent with 
the presence of a minor clone carrying the chromosome 3 deletion in the patient cells at 
presentation.(11) 
Suggestive of convergent clonal evolution and highlighting the relevance of specific chromosomal 
regions to disease progression, several were targeted by different abnormalities segregated in 
xenografts from the same patient. Consistent with an oncogenic role for genes on Xp, patient 2 
carried competing sub-clones marked by gain of a whole X chromosome or isochromosome Xp 
(Figure 3B). Whether emergence of a focal deletion of Xp, involving the zinc finger genes, ZNF157 
and ZNF41, was related to the presence of the larger scale CNA remains unclear but they were 
unlikely to have been driven by CRLF2 overexpression, as genetic analysis ruled out rearrangement 
of this locus in the patient sample(25). In patient 3 large overlapping deletions of 12p, both involving 
ETV6, were segregated (Figure 3C). Although no patient material was available, revealing differences 
in CNAs involving the long arm of chromosome 10  were identified in xenografts from a relapse 
sample of patient 4 (Figure 3D). Strongly indicative for convergent evolution and hence a role in 
leukemia progression, the same focal bi-allelic deletion, involving PIK3AP1 (BCAP) and LCOR 
(C10orf21), was nested within two distinctly different, large, mono-allelic 10q deletions. Evidently of 
independent origin, as it was detected only in a single xenograft, one of the large deletions also 
harboured a second likely co-operating focal bi-allelic deletion that resulted in loss of BLNK. Lastly 
passage of patient 5 cells in a primary xenograft resulted in concomitant loss of CN-LOH of 12q, with 
progression from sub-clonal to clonal deletion of a region of 12q containing SH2B3 (Figure 3E). 
Comparison between relapse and the xenograft showed no overlap in progression of specific CNA, 
although interestingly the EBF1 gene was targeted by different deletions in the two samples.  
Mutations affecting the RAS pathway drive clonal expansion. 
To investigate progression of mutations activating the RAS pathway previously identified in patient 
1(13) we performed whole exome sequencing of selected and Sanger sequencing of all derived 
 xenografts (Fig 4a). Interestingly while an NF1 mutation remained clonal in all samples, two different 
mutations affecting NRAS and one of KRAS marked a dramatic clonal evolution. Remarkably the 
KRAS mutation, present as a dominant clone in both primary and one secondary xenograft was 
undetectable at a read depth of over 6000 in the presentation sample and also undetected in other 
xenografts which instead carried a dominant NRAS mutation detected in only 1% of reads at 
presentation.  NRAS and FLIT3 mutations detected at presentation in patients 3 and 5 respectively 
were clonal in xenografts while the FLIT3 mutation was lost at relapse (Figures 4b and 4c).  
Transcriptional environment associated with deletions.  
Anticipating that xenograft preparations, in contrast to patient samples, would be free of non-
leukemic human cells, we used them to investigate the transcriptional environment associated with 
bi-allelic deletions (Table 3). By comparison with non-deleted samples, and confirming clonal 
dominance of the chromosome 10 deletions, we saw marked reductions in the levels of transcription 
of PI3KAP1, LCOR and BLNK. Loss of the BLNK genomic region also resulted in silencing of DNTT and 
OPALIN. Three of the four sequenced xenografts carried bi-allelic 9p deletions affecting CDKN1A/B. 
Indicating strong pressure for clonal selection of bi-allelic loss, read counts within this region were 
reduced to zero in deleted cases. Interestingly two focal bi-allelic deletions were associated with 
silencing not only of the physically deleted genes but also of TUSC1, positioned more than 3 Mb 
away from the deletion boundaries.  
Discussion 
Compared with genetically engineered animal models, xenografts bring several advantages to the 
study of ALL, not least, their potential to fully recapitulate the spectrum of genomic abnormalities 
that occur within individual patients of a given genetic sub-type. This is particularly relevant to 
iAMP21-ALL, where the primary abnormality is structurally complex, unique to each patient and 
impossible to reproduce in engineered animal models. As there are no cell lines carrying iAMP21, 
 the xenografts presented here represent an important resource for future functional and pre-clinical 
studies. 
Highlighting the potential of lentiviral constructs integrated into xenograft cells, we demonstrated 
their in vivo expression. However we observed considerable temporal and spatial variation in signal 
development that, as demonstrated by analysis of spleen and CNS, was apparently related to heavy 
skewing of the ratios of transduced to non-transduced cells at specific sites. It seems likely that this 
skewing was caused largely by clonal expansion of small founder populations, particularly as tracking 
of specific genomic abnormalities demonstrated aggressive expansion of minor sub-clones in 
xenografts. As a consequence, accurate analysis of disease burden by in-vivo imaging, will in future 
require enrichment for EGFP expressing cells prior to engraftment.  
Unexpectedly, light microscopy and TEM together provided strong evidence that transplantation of 
NSG mice with iAMP21-ALL cells from two patients led to destruction of the bone marrow niche. As 
we saw no examples of similar morphology among iAMP21-ALL patient samples, it seemed likely 
that this phenomenon was xenograft specific and a consequence of initiating a heavy leukemic 
burden at one site. Cells populating the affected areas, although damaged, were heterogeneous and 
showed little if any staining with human CD19 and CD45 suggesting they were of host origin. 
Histology was therefore consistent with destruction having occurred in areas of normal bone 
marrow before malignant cell infiltration suggesting systemic suppression of normal 
haematopoiesis, possibly through a mechanism such as cytokine scavenging, as recently reported to 
account for cytopenia in AML.(26) The effect did not correlate with late stage disease, as mean time 
between transplant and cull were almost identical and spleen weights were higher and CNS 
infiltration heavier for mice with no evidence of niche destruction. Further analysis demonstrated 
that niche destruction is not restricted to the iAMP21-ALL sub-type but is probably less common 
than suggested by our initial data. 
 Global analysis of iAMP21-ALL patient and xenograft genomes revealed a dynamic branching of 
genomic architecture, similar to that reported previously for B-ALL.(4, 6, 7, 27, 28) However the rate 
of newly emergent CNA and their diversity in iAMP21-ALL xenografts suggested a LIC compartment 
characterised by greater genetic heterogeneity compared with other B-ALL sub-types. Genomic 
arrays revealed an average of five CNA changes per transplanted iAMP21-ALL sample, while similar 
analysis defined only a single change among seven KMT2A rearranged infant ALL samples engrafted 
into multiple mice.(28) Additionally, among 12 BCR-ABL1-positive ALL samples, half showed no CNA 
discordance in xenografts.(27) The iAMP21-ALL primografts also developed disease with a relatively 
long latency. Together with the older patient age at diagnosis of iAMP21-ALL(12), these data suggest 
that the primary iAMP21 rearrangement confers only a moderate growth advantage, producing an 
indolent disease course over which diverse genetic sub-clones are sampled. As genetic diversity has 
been linked to clinical aggressiveness,(29) this clonal heterogeneity of iAMP21-ALL may underlie 
their poor response to standard therapy.(17)  
Although each iAMP21 chromosome is unique with respect to the balance of regions amplified and 
deleted, within clinical trials, these patients are treated homogeneously.(17) Our data support this 
approach, as they further confirm iAMP21 to be a primary abnormality, because the region 
identified as consistently amplified and spared from chromothripsis,(11) was always retained. 
However in xenografts from one patient, we observed segregation of a structurally evolved iAMP21 
chromosome which, together with other CNA, marked a clone that appeared to confer an 
exceptionally strong growth advantage. Structural evolution of iAMP21 has not been reported 
previously, although only few presentation/relapse pairs have been analysed at the whole genome 
level and FISH is usually targeted only to the RUNX1 gene. This case demonstrates that even after 
stabilisation of the iAMP21 chromosome evident at the time of diagnosis, these rearrangements can 
undergo further evolution, potentially influencing clinical features and treatment response. However 
this iAMP21 chromosome may be atypical, as it was reported to be a ring chromosome, which are 
known to be inherently unstable structures.(30)  It may be that other iAMP21 ring chromosomes 
 have a tendency to further evolution, but this case was the only one included in this study. Whether 
this iAMP21 chromosomal evolution acted as a driver of leukemia progression remains uncertain, as 
it was co-selected with other abnormalities, including an NRAS mutation and bi-allelic loss of 
CDKN2A/B. Among the four other cases transplanted, three were affected by concordant or 
discordant CDKN2A deletions, two bi-allelic and one mono-allelic, detected by MLPA only and 
without apparent involvement of CDKN2B. Further suggesting strong selective pressure for loss of 
CDKN2A/B in the xenografts, as evidenced by RNA sequencing data, the bi-allelic deletions were all 
highly clonal. As deletion of this locus only occurs in about 12% of iAMP21-ALL patients(21), these 
observations support previous reports that CDKN2A/B loss is associated with rapid disease 
manifestation(27) and is selected for in B-ALL xenografts,(4) and are also in keeping with a xenograft 
specific expression signature enriched for cell cycle genes.(31) Alternative mutations of NRAS and 
KRAS were also strongly selected and both apparently co-operated with an NF1 mutation in 
xenografts. To our knowledge NF1 and RAS mutations have always been reported as mutually 
exclusive in B-ALL patients, although their co-occurrence in Juvenile myelomoncytic leukemia has 
been associated with aggressive disease. In mouse models, a combination of NF1 deficiency and 
KRAS activating mutation reduced the latency of myeloid malignancy compared with either 
abnormality alone (13, 32, 33).  
Other chromosomal regions were strongly implicated in ALL progression, as targets of overlapping 
abnormalities segregated in different clones of xenografts. These included genes known to be 
involved in B-ALL; ETV6, SH2B3 and BLNK (SLP-65),(34-36) as well as novel candidate tumour 
suppressor genes. Two distinct large deletions, selected in different xenografts, resulted in 
conversion to homozygosity of a micro-deletion involving PIK3AP1 and LCOR. PIK3AP1 encodes an 
adaptor protein linking the B-cell receptor (BCR) and CD19 to activation of PI3K/Akt.(37-39) A similar 
function in the transduction of pre-BCR signalling is likely and, although not previously implicated in 
childhood leukemia, focal deletions of PIK3AP1 have been reported in three cases of adult B-ALL.(40, 
41) Combined with our evidence for strong selective pressure for its conversion from mono to bi-
 allelic deletion, PIK3AP1 is an interesting candidate, possibly worthy of addition to the growing list of 
pre-BCR related genes disrupted in childhood B-ALL.(42) However a role for LCOR, which functions as 
a co-repressor of several nuclear hormone receptors,(43) and has been reported to interact with 
methyltransferase complexes including polycomb repressive complex 2,(44) should not be 
discounted.  
In conclusion, we present the first successful xenografts of iAMP21-ALL and demonstrate their 
potential as experimental models for functional investigation of this poorly understood genetic 
subtype. These xenografts could also serve as models in pre-clinical trials or for personalised 
medicine, with the caveat that systemic niche destruction occurred in some cases. Tracking of CN 
abnormalities, to investigate genomic evolution in xenografts, revealed a surprisingly high rate of 
instability and examples of marked divergence in CN status of known leukemia driver genes.  Further 
genomic screening of iAMP21-ALL xenografts is likely to reveal many more clonal abnormalities 
undetected in patient samples, augmenting data generated from clinical trial cohorts, as well as 
potentially guiding treatment in individual cases.  
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 Table 1. In-vivo and ex-vivo luminescent imaging data and spleen weights for xenografts 
transplanted with iAMP21-ALL cells transduced with pSLIEW. 
 
 
 
*blasts are CD19 +ve cells isolated from spleen.  
 
Xenograft 
Whole Body Luminescence 
(photons/second) 
Dissected Organ Luminescence 
(photons/second) 
Spleen weight/ 
% GFP +ve 
blasts*   
Peak whole 
body 
(PWB) 
Peak 
injected 
femur (PIF) 
Ratio 
PWB/PIF 
Spleen Liver 
Kidney 
(mean) 
Spleen 
radiance/g 
4
SLIEW
a 6.87E+08 2.53E+08 2.72 ND ND ND ND 0.83g / 0.2  
4
SLIEW
b 2.97E+08 5.09E+07 5.84 ND ND ND ND 0.81g / 0.0 
3
SLIEW
a 1.64E+09 1.90E+08 8.63 5.69E+08 3.77E+07 1.49E+05 2.47E+09 0.23g / 44 
3
SLIEW
b 1.81E+09 4.00E+08 4.53 3.85E+08 1.99E+07 3.02E+05 1.43E+09 0.27g / 68% 
1
SLIEW
a 3.79E+08 2.44E+07 15.53 1.12E+07 4.10E+06 2.50E+05 2.11E+07 0.53g / 1.6% 
1
SLIEW
b 1.57E+08 1.43E+07 10.83 2.60E+07 4.27E+06 1.84E+05 2.95E+07 0.88g / 0.8% 
2
SLIEW
a 3.30E+09 1.06E+08 31.13 1.04E+09 9.84E+07 3.67E+05 2.60E+09 0.40g / 24% 
2
SLIEW
b 3.65E+09 3.64E+08 10.03 3.10E+09 1.83E+08 6.65E+05 5.64E+09 0.55g / 26% 
 Table 2: Summary of histological and ultrastructural (EM) data for bone marrow and CNS of mice 
transplanted with iAMP21-ALL cells. 
 
 
 
*Units of luminescence are total flux (photons / second). 
 
  
Xenograft                                  Tibia/sternum Calvaria CNS 
H&E CD19 CD45 Ki67 EM H&E CD19 (grade) 
Peak head 
luminescence* 
4a
SLIEW
 A +ve +ve +ve VL N/A +ve N/A 8.3x10
7
 
4b
SLIEW
 A +ve +ve +ve VL A +ve 5 3.4x10
7
 
   3a
SLIEW
 A +ve -ve +ve AP A +ve 1-2 3.4x10
8
 
3b
SLIEW
 A/B +/-ve -ve +/-ve AP A +ve 1-2 2.3x10
8
 
1a
SLIEW
 A +ve +ve +ve VL A +ve 3-4 + CP 3.7x10
7
 
1b
SLIEW
 A +ve +ve +ve VL A +ve 4 6.4x10
6
 
2a
SLIEW
 A +ve -ve +ve AP A +ve 1 3.7x10
8
 
2b
SLIEW
 B -ve -ve -ve AP A +ve 2 6.3x10
8
 
 Table 3. The expression of genes in xenograft derived iAMP21-ALL cells within and neighbouring 
regions of bi-allelic deletion of chromosomes 10 and 9. 
 
 
Gene expression units are read counts / million (RCM). Regions of complete / near complete loss of 
expression and copy number (CN) of 0 are highlighted. 
Chromosome 10 Xenograft 
    3°1e 1°4b 2°2e 2°3d 
Gene Genomic position  RCM CN RCM CN RCM CN RCM CN 
ZNF518A 
96,129,715-96,205,288 
3513 2 2746 1 2474 2 3316 2 
BLNK 
96,191,702-96,271,587 
18573 2 21 0 11315 2 6251 2 
DNTT 
96,304,396-96,338,564 
166450 2 344 1 170269 2 215495 2 
OPALIN 
96,343,216-96,359,365 
458 2 2 1 698 2 471 2 
TLL2 
96,364,606-96,513,918 
235 2 1 1 152 2 111 2 
TM9SF3 
96,518,109-96,587,452 
14506 2 8325 1 12641 2 19522 2 
PIK3AP1 
96,593,312-96,720,514 
35985 2 4 0 20616 2 28820 2 
LCOR 
96,832,260-96,981,043 
8942 2 21 0 7568 2 4218 2 
SLIT1 
96,998,038-97,185,920 
0 2 0 1 0 2 0 2 
ARHGAP19 
97,222,173-97,292,673 
2486 2 4151 1 3164 2 3524 2 
Chromosome 9                 
MTAP 
21,802,543-21,937,651 
1 0 918 1 2 0 1846 2 
CDKN2A 
21,967,753-21,995,301 
0 0 0 0 0 0 883 2 
CDKN2B 
22,002,903-22,009,363 
0 0 0 0 0 0 62 2 
CDKN2B-AS1 
21,994,778-22,121,097 
0 0 0 0 0 0 82 2 
DMRTA1 
22,446,841-22,455,740 
0 0 0 1 0 1 0 2 
ELAVL2 
23,690,104-23,826,337 
0 0 0 1 0 1 0 2 
TUSC1 
25,676,389-25,678,440 
0 0 0 1 0 1 415 2 
CAAP1 
26,840,685-26,892,804 
0 0 686 1 576 1 1307 2 
PLAA 
26,904,083-26,947,463 
1 0 1411 1 1230 1 1939 2 
  
Figure Legends. 
 
Figure 1. In Vivo and ex-vivo imaging of xenografts. 
A. Serial quantification of luminescent signal from injected and contralateral femurs and the whole 
body for each xenograft suggesting variations in the rate at which cells migrate from the site of 
injection and the degree to which different sites are infiltrated by transduced cells. For example, in 
3a/b
SLIEW
 the strength of signal from the contralateral femur lagged substantially behind that of the 
injected femur until weeks 10-13, while in 1a/b
SLIEW
 and 2b
SLIEW
, the two femurs showed similar levels 
from week 2.  B. Example of ex-vivo imaging of dissected organs showing total luminescent readings 
for spleen liver and kidney. Images are representative of six animals analysed. C. Examples of FACS 
analysis of cells isolated from the spleens of 3a
SLIEW
 and 4a
SLIEW
, demonstrate marked contrast in the 
proportion of CD19+ve cells that are EGFP+ve. D. A single example of serial three dimensional 
reconstructions of luminescent signals in 2a
SLIEW
, 11 and 15 weeks after transplant. Arrows point to 
regions of the skull, spleen and a third site showing strong signal increase between these two time 
points. The skeleton projected for orientation is not derived from this animal. 
Figure 2. Histological sections of bone marrow from controls and xenograft transplanted with 
SLIEW transduced cells.   
A. Control NSG mouse H&E stained femur showing heterogeneous cell types, abundant 
megakaryocytes and vascular structures. B. H&E stained femur from 4a
SLIEW
 showing tightly packed 
homogeneously stained cells and an absence of megakaryocytes and vascular structures (image 
representative of six animals showing only morphology type A) C. H&E stained femur from 3b
SLIEW
 
showing heterogeneous cell types but in comparison with controls; loss of cellularity and 
organisation, absence of vascular structures, reduced numbers of megakaryocytes and presence of 
small darkly stained cells or cellular fragments (image representative of two animals showing 
 morphology type B) D.  The only example seen of co-existence of A and B type morphology in a 
sternum segment of 3b
SLIEW
: 1st left panel; H&E stained whole section with box marking the region 
shown in the 2
nd
 left panel. 2
nd
 left panel; H&E stained detail of a single sternum segment displaying 
both A and B type morphologies. Middle panel; whole sections stained with anti-human CD19 and 
Ki-67 antibodies, arrowheads indicate three regions corresponding to high resolution images in the 
right hand panels. Right hand panels; high resolution images of anti-CD19 and Ki-67 staining from 
regions 1, 2 and 3. Anti-CD19 and Ki67 stained human leukemia cells remain tightly packed (region 2) 
with little diffusion to adjacent areas of acellular marrow (region 3). Anti-Ki67 and CD19 staining 
demonstrating that the proportion of cycling human cells are reduced in region 2 compared with 
region 1 suggesting a microenvironment less favourable for leukemia cell growth.  E. Examples of 
TEM images of xenograft tibia sections. In 4a
SLIEW
 and 1a
SLIEW
 cells appear homogeneous compared 
with controls (Supplementary Figure 6) and have a high nuclear to cytoplasmic ratio (VL 
morphology). 3a
SLIEW
 and 2a
SLIEW
 displaying evidence for cell death and characteristics of apoptosis, 
such as chromatin clumping and nuclear fragmentation (AP morphology). Images are representative 
of four animals each showing VL and AP morphology.  F. Examples of skull and brain sections from 
3b
SLIEW
 (left panel) and 1b
SLIEW
 (right panel) showing heavy infiltration of the calvaria in both cases 
(arrow 1), light (3b
SLIEW
) and heavy (1b
SLIEW
 ) infiltration of the meninges, respectively (arrow 2). 
Images are representative of seven animals. G. Two examples of H&E stained patient trephines. The 
left hand panel is from patient 1 for comparison with the leukemia cells from the same patient in a 
mouse (1a
SLIEW
) tibia section shown in B. Images are representative of seven iAMP21-ALL patient 
trephines analysed. Scale bars are; A, B, C, two right hand panels of D and G - 50 µm, far left hand 
and two middle panels of D – 1 mm, second from left panel of D and F 200µm and E - 10µm. 
Figure 3. Analysis of CNA evolution in xenografts models.  
Panels in blue boxes show heat maps of copy number from SNP6.0 arrays for chromosomal regions 
showing evidence of clonal genomic evolution in xenografts, P (presentation), R (remission), 1°,2°
 
and 3° (primary, secondary and tertiary xenografts). Box-flow diagrams illustrate loss, gain or change 
 in level of genomic abnormalities. White boxes; sample analysed, grey boxes; sample not analysed, 
red type; CN gain of one, purple; CN gain of two, light red; sub-clonal CN gain, black; CN loss of one, 
blue; CN loss of two, grey; sub-clonal loss, green CN-LOH. * indicates deletion was detected by whole 
genome sequencing but not by SNP6.0 array. A. Patient 1 – including heat maps of 9p demonstrating 
gain of bi-allelic deletion of a region containing CDKN2A/B and focal mono-allelic deletion of a region 
of 3p containing the CMTM genes 6-8. Chromosome 21 heat maps illustrate a complex pattern of 
copy number gain and loss characteristic of iAMP21 and also demonstrate additional CN changes in 
one 2° and all 3° xenografts. The colour coded bar depicts regions of chromosome loss or gain in the 
derivative iAMP21, [der(iAMP21)]. Green box; chromosome 21 CN profiles before and after iAMP21 
evolution and showing the position of probes used for FISH analysis. Upper black box; FISH image of 
metaphase and interphase cells showing multiple copies of the RUNX1 region and 3 copies of the 
APP region at presentation. Lower black box; FISH images showing three or one copy of the APP 
region in cells from the patient, a 1° and two 2° xenografts. B. CNAs discordant between patient 2 
and xenografts including; loss of whole chromosome (WC) X, gain of an iso(Xp) and gain of a focal 
deletion of Xp involving the genes ZNF157 and ZNF41.  C. CNA discordant between patient 3 and 
xenografts including different deletions involving ETV6 one of which potentially resulted in a novel 
ETV6-BICD1 fusion gene. D. Differences in copy number profiles between three 1° xenografts from 
patient 4. These included two different large mono-allelic deletions of chromosome 10 (1 and 2) 
both of which contained a focal bi-allelic deletion (3), present in all xenografts and involving PIK3AP1 
and LCOR. A second bi-allelic deletion (4) was present in two xenografts only and involved BLNK. 
Other discordant CNA included complex rearrangements of 17q and 14q, focal deletions of 4q34.1, 
16p13 and 22q13.1 and a focal amplification of 4q13.2. E. Sub-clonal deletions at 2p25.1, 3q13.3 and 
12q24.1 present in patient 5 became dominant clones in the xenograft while a sub-clonal deletion of 
3p21.3 was lost and sub-clonal deletions of 1q42.3 and 5q33.3 (marked by red arrow 1) were gained. 
In the patient relapse sample the 3p21.3 deletion became dominant while other sub-clonal 
abnormalities detected at presentation were lost. As with the xenograft a focal deletion of 5q33.1 
 (marked by red arrow 2) emerged at relapse. The two 5q deletions both resulted in loss of coding 
exons of EBF1. Genomic positions of breakpoints derived from SNP6.0 analysis and genes contained 
within focal CNA, for all patient and xenografts, are annotated in Supplementary Table 7.  
Figure 4. Analysis of mutations affecting the RAS pathway. Key for analytical methods used are 
shown top right. Blue boxes show non-synonymous RAS pathway mutations identified. White boxes 
summarise the estimated variant allele (VA) frequencies and methods of analysis used for patient 
and xenograft samples. A) In patient 1 an NF1 mutation was clonal at presentation and in all 
xenografts. By contrast mutations of NRAS and KRAS showed marked fluctuations in VA frequency; 
NRAS (1), present in the patient as a sub-clone, was detected in both 1° xenografts but not in blasts 
from 2° and 3° animals. NRAS (2), identified by high depth targeted sequencing in 1% of patient 
sample reads, was undetected by whole exome sequencing in primografts but emerged as a 
dominant clone in 2°2a and all derivative 3° xenografts. A mutation of KRAS, although undetected in 
more than 6000 reads by targeted sequencing of the patient sample, marked the dominant clone 
present in primografts and 2°2b. Sanger sequence traces illustrate the relationship between the NF1, 
NRAS (2) and KRAS mutations in the two 2° xenografts, traces shown for 2°1a are also representative 
of 1°1a and 1°1b, traces shown for 2°1b are also representative for 3°1a-g. B) In patient 3 an NRAS 
mutation identified in the patient remained clonal in all 1° and 2° xenografts. The Sanger sequencing 
trace shown for 1°3a is representative of all xenografts. C) In patient 5 a FLT3 itd, detected as a 
minor sub-clone by exome sequencing of the presentation sample, became dominant in the 1° 
xenograft as demonstrated by the generation two distinct exon 14 PCR amplicons of equal intensity 
(first lane bottom right). In contrast only a single PCR product was amplified from the relapse sample 
of this patient (second lane bottom right).  Mutations detected in patient presentation samples have 
been previously published.(13) 
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Supplementary methods 
Determination of xenograft experimental end points. Mice were checked daily for signs of ill health 
and routinely weighed once a week or more often if indicated. Mice were culled at end stage disease 
as defined by; weight gain of >20%, weight loss reaching 20% at any time or >10% maintained for 72 
hours compared with weight at the start of the experiment, starey coat, porphyrin staining of eyes 
and nose or sunken eyes, persistent skin tenting, immobility, unresponsive or very aggressive 
behaviour, loss of upright stance, laboured respiration, blood staining or other discharge, signs of 
anaemia including extreme paleness of feet, tail and ears. 
Immunophenotyping of xenografts cells. Proportions of human and mouse cells were determined 
by flow cytometry using anti-human CD10 FITC or CD19 PE in combination with anti-murine-CD45, 
PE-Cy7 and anti-TER119 PE-Cy7, as previously described.(1) Selected xenografts were further 
characterised using a panel of anti-human CD19-APC, CD10-PE, CD34-Cy5.5 and CD38-FITC together 
with anti-mouse CD45-Cy7-A. Cells were initially gated on a lymphocyte population defined by 
forward and side scatter and on the anti-mouse CD45 negative population. For each sample, 
identical markers were used to divide the gated cells into human CD19, CD10, CD45 and CD38 
negative and positive populations based on median fluorescence intensity (MFI) of the unstained 
cells. MFI and % positive cells (supplementary table 5) refer to the total gated population with the 
exception of a minority of samples where the proportion of cells staining positively for mouse CD45 
was high and a significant proportion of gated cells, negative for all human markers, was assumed to 
be of mouse origin and gated out. All antibodies were obtained from BD Biosciences (Oxford, UK) 
and stained cells were analysed with a BD FACSCanto II cell analyser and processed with FlowJo 
(Oregon, USA) software .  
Lentiviral transduction, In-vitro culture and in-vitro, in-vivo and ex-vivo imaging of xenograft cells. 
SLIEW lentivirus was produced as previously described(1) with the modification that HEK293FT cells 
(Thermo Fisher Scientific) and EndoFectin (GeneCopoeia) transfection reagent were used. Lentiviral 
stocks were concentrated by ultracentrifugation for 2 hours at an RCF of 83018 and re-suspended in 
Serum free expansion medium (SFEM) (Stemcell Technologies) supplemented with 10% FCS before 
titrating in 293FT cells. For each patient analysed, 1.2x107 xenograft cells in SFEM supplemented 
with 10% FCS and 10ng/ml IL-7, were transduced at a multiplicity of infection of 1.0 in delta T25 
tissue culture flasks. Following overnight incubation medium was replaced and approximately 72 
hours after transduction 0.5x106 cells were analysed for EGFP expression by FACS, 1.5x106 cells were 
transplanted into each of two NSG mice and 6x106 cells were re-suspended in αMEM with 10% FCS 
for in-vitro co-culture. Co-cultures were established by plating 2x106 transduced xenograft cells in 
1ml of medium on MS-5 cells (DSMZ # ACC441) (83,000 cells plated /well in 12 well plates) that had 
been irradiated with 50 Gy 24hrs after plating. EGFP expression of co-cultured cells was assessed 
using an EVOS fluorescent inverted microscope (Life technologies). 2D and 3D bioluminescent whole 
body imaging of mice transplanted with transduced xenograft cells was performed with an IVIS 
Spectrum (Caliper Life Sciences, Hopkington, MA, USA) 10 minutes after intraperitoneal injection of 
100ul of D-luciferin (30mg/ml, VivoGlo, Promega). Immediately following final whole body imaging 
mice were killed and organs dissected and imaged ex-vivo. Quantification of luminescent signals and 
3D reconstructions were performed using Living image version 4.3.1 software (Caliper Life Sciences). 
The proportion of leukaemia cells expressing SLIEW in spleen preparations was measured by 
immunostaining and FACS by determining numbers of EGFP+ve cells in the human CD19+ve and / or 
CD10+ve, murine CD45 / TER119 –ve population.  
Histopathology.  
After transfer to 10% neutral buffered formalin immediately after dissection, tibias and sternums 
were decalcified, paraffin embedded, sectioned and stained with haematoxylin and eosin (H&E) or 
human antibodies, according to standard histopathological techniques, by the department of 
Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust. Mouse heads preserved in 
formalin were sectioned and stained as previously described.(2)  
Transmission Electron Microscopy (TEM). TEM was performed by the Electron Microscopy Unit, 
Faculty of Medical Sciences, Newcastle University. Small trephines of bone were fixed in 5% 
glutaraldehyde in 3% PFA in phosphate buffer overnight. Samples were then rinsed in phosphate 
buffer before being placed in EDTA for a minimum of 24hrs at 40OC. After rinsing in phosphate buffer 
the samples were placed in 1% osmium tetroxide for 2hrs at RT. They were then rinsed in buffer, 
dehydrated through a graded series of acetone and embedded in TAAB epoxy resin (medium). After 
polymerisation at 60OC the samples were sectioned on an ultramicrotome and ultrathin sections 
(70nm) were picked up on copper grids, stained with uranyl acetate and lead citrate and viewed on a 
Philips CM100 TEM at 100kV. 
RNA Sequencing.  
RNA was extracted from cells isolated from xenograft spleens and purified over Ficol using an 
RNeasy kit (Qiagen). Illumina RNA sequencing was performed by Aros Applied Biotechnology, 
Eurofins Genomics Group, Aarhus, DK. 
Analysis of RAS pathway mutations. Whole exome sequencing (WES) was performed on selected 
xenografts derived from patient 1 using library preparation and sequencing techniques as previously 
described(3). To filter mouse sequences from xenograft samples, the programme, Xenome v 1.0.1, 
was used to simultaneously align reads to version GRCm38 and hg19 of the mouse and human 
genomes, respectively(4). Default settings of xenome index and classify were used to designate 
reads as of human or mouse origin, ambiguous, both or neither, with only unambiguous human 
reads used for subsequent analysis. Reads were aligned using Burrows-Wheeler Aligner (BWA) 
version 0.7.12.(5, 6) and MuTect1.7 (7) was used for calling somatic single nucleotide variants (SNVs) 
following Broad Best practices(8, 9). Calls were derived from jointly realigned and recalibrated 
tumour normal (patient remission sample) BAM files and annotated with ENSEMBL Variant Effect 
Predictor (VEP) version 83(10). Patient BAM files were re-analysed manually in Integrated Genome 
Viewer(11) to assess levels of SNV affecting the RAS pathway, predicted to have an oncogenic role 
(mutations located within coding regions and predicted to affect protein function using SIFT, 
Polyphen2 and Mutation Taster) and identified by WES in xenografts but not previously in the 
patient (KRAS, chr12:25380276, T->A; NRAS, chr1:115258744, C->T). 
To validate clonal SNV affecting NF1, NRAS and KRAS and extend analysis to remaining patient 1 
xenografts, affected exons were amplified and analysed by sanger-sequencing (Durham Genome 
Centre, Durham UK). Sequence traces were examined manually using FinchTV (Information 
Technologies, Inc, MO, USA). Target sequence amplification and Sanger-sequencing was also used to 
analyse an NRAS mutation in xenografts, previously identified in patient 3. Levels of a FLT3 30 
nucleotide internal tandem duplication (ITD) identified in patient 5 were assessed in xenografts and 
a relapse sample using targeted sequencing in combination with electrophoretic analysis of amplicon 
size using a 2100 Bioanalyzer (Agilent technologies, CA USA). All primer sequences used for exon 
amplification have been previously published (3).  
 
 
 
 
 
 
 
  
Supplementary Figures 
 
 Supplementary Figure 1. FACS analysis demonstrates immunophenotypic heterogeneity between 
xenografts. Expression of CD19, CD34, CD10 and CD38 are shown for bone marrow (BM) and / or 
spleen samples for xenografts from patients 1-4 as indicated. Scales are bi-exponential and units are 
arbitrary.  
  
Supplementary figure 2. FACS analysis of iAMP21-ALL cells isolated from xenografts transduced 
with SLIEW lentivirus prior to transplant. FACS plots showing levels of EGFP expression (arbitrary 
units) in control (green trace) or transduced cells (purple infill). Live cells were gated on forward and 
side scatter as shown in the right hand box. In all cases the proportion of cells with GFP levels 
outside the control range (marker by M1) were less than 1%.  
  
Supplementary Figure 3. Serial bioluminescent imaging of all NSG mice transplanted with pSLIEW 
transduced iAMP21-ALL xenograft derived cells. Measurement of luciferase activity demonstrates 
variation in the rate of spread of leukaemia from the site of injection to other bones and organs. 
Spleen involvement (marked by red arrows) was most obvious in 1aSLIEW 1bSLIEW, 2aSLIEWand 2bSLIEW but 
undetectable in 4a/bSLIEW. All captured images are shown. Scale is radiance (p/sec/cm2/sr).  
 Supplementary Figure 4. Histological sections of control and SLIEW transduced iAMP21-ALL 
xenograft bone marrows. 
Sections of NSG control and xenograft mouse tibias stained with H&E and anti-human CD19, CD45 
and Ki67. 4aSLIEW, 4bSLIEW, 3aSLIEW, 1aSLIEW, 1bSLIEW and 2aSLIEW have packed homogeneous cells similar to 
those seen in iAMP21-ALL patient trephines (Figure 2G and Supplementary Figure 5), that stain 
positively for human CD19 and Ki67 and for CD45 in 4aSLIEW, 4bSLIEW,  1aSLIEW and 1bSLIEW only 
(morphology type A). 3bSLIEW and 2bSLIEW show loss of cellularity and evidence for apoptosis and stain 
negatively for CD19, CD45 and Ki67 (morphology type B). In each case the image shown is 
representative of all bone marrow in the section analysed. Scale bars are 50µm. 
 
  
Supplementary Figure 5. iAMP21-ALL patient trephines. H&E stained sections through iAMP21-ALL 
trephine sections showing morphology similar to that of xenograft type A (Figure 2 and 
Supplementary Figure 4) with packed homogeneous cells and loss of vasculature and 
megakaryocytes. Patient karyotypes and demographic details are provided in supplementary table 2. 
In each case the image shown is representative of all bone marrow in the trephine section. Scale 
bars are 50µm. 
 
 Supplementary Figure 6. Transmission electron microscopy (TEM) of control and SLIEW transduced 
iAMP21-ALL xenograft bone marrows.  
TEM of ultra-thin sections of xenograft bone marrow; 4aSLIEW, 4bSLIEW, 1aSLIEW and 1bSLIEW have 
homogeneous cells with high nuclear to cytoplasmic ratio (VL morphology), compared with the 
control section, they lack vascular structures and cellular heterogeneity. 2aSLIEW, 2bSLIEW, 3aSLIEW and 
3bSLIEW show loss of cellularity and evidence for apoptosis, such as chromatin clumping and nuclear 
fragmentation (AP morphology). Each image is representative of 6 regions captured from a single 
tibia section. Scale bars are 10µm. 
 Supplementary Figure 7. SLIEW transduced Xenograft CNS histological sections.  
A. H&E stained low powered image of a coronal section through the brain and skull of 1aSLIEW with 
major structures and areas of leukaemia infiltrate marked with arrows. Scale bar is 1 mm. Leukaemic 
deposit on the surface of the brain in the region marked in box 1 is shown in detail in B (stained with 
H&E) and in C (stained with anti-human CD45). Scale bars are 100µm. D-G H&E stained detail of the 
dural sinus region, marked by box 2 in A, showing varying degrees of leukaemic infiltrate of the 
leptomeninges marked by arrows, in xenografts from; 4bSLIEW (D), 2aSLIEW (also representative of 
2bSLIEW ) (E), 3aSLIEW (also representative of 3bSLIEW) (F) and 1aSLIEW (also representative of 1bSLIEW)(G). 
Scale bars are 100µm.   
 Supplementary figure 8. Histological sections of additional xenografts showing both A and B type 
morphology. Upper and lower left hand panels show low magnification image of H&E stained 
sections of fibia and sternum and of the fore limb of xenografts derived from a relapsed iAMP21-ALL 
(1°5Rb) and a high hyperdiploid ALL respectively (1°17a). Right hand panels show high magnification 
H&E and human anti-CD19 stained images of regions marked in the left hand panels by arrows. 
Regions 1 and 2 of the 1°5Rb section and region 1 of the 1°17a section show A-type morphology. 
Region 3 and 4 of 1°5Rb and region 2 of 1°17a show B type morphology.  Scale bars are 1500um and 
50um for low and high magnification images respectively. 
  
  
Supplementary Figure 9. Histological sections of additional xenografts showing A type morphology 
only. High magnification images of bone marrow sections stained with H&E and CD19 taken from 
tibias, fibias or sternum of additional primografts. The regions shown are representative of all bone 
marrow observed in a single section of 1 or 2 bones. Scale bars are 50µm. 
  
 Supplementary Figure 10. Histological sections of additional xenografts showing patches of A-type 
morphology infiltrating apparently normal mouse bone marrow. Left hand panels show low 
magnification images of human anti-CD19 stained sections of iAMP21 xenografts showing areas of 
positively and negatively stained cells. Right hand panels show high magnification H&E and anti-
CD19 staining for the same sections. In all three sections infiltrating leukaemia cells are organized 
into clumps with non-infiltrated areas resembling normal mouse bone marrow. The images shown 
are representative of a single section of 1 or 2 bones. Scale bars 300 and 50um for low and high 
magnification images respectively. 
 Supplementary Figure 11. SNP6.0 chromosome 21 CN profiles for all patient and xenograft 
samples analysed.  
Samples from presentation (P), remission (R) and xenografts. With the exception of patient 1, 
profiles were indistinguishable between patient leukemia and/or across xenograft samples.  
Supplementary Tables 
Supplementary Table 1. Karyotypes and demographic details of iAMP21-ALL patient samples used 
to create xenografts 
 
 
Age and white blood cell count (WBC) are at diagnosis. *Normal population excluded from abnormal 
karyotypes. ** Sample was from a case which relapsed in the CNS with no evidence for iAMP21 by 
interphase FISH of the bone marrow indicating that the blast count was low in this sample. 
Previously published IDs refer to previous publications; A - Harrison et al 2014(12) B - Ryan et al 
2016(3). 
 
 
 
 
  
 
Patient 
registration 
number  
 
ID this 
study 
 
Presentation (P) 
/relapse (R) 
 
Karyotype* 
 
Age 
(years) 
 
Sex 
 
Previously 
published patient 
ID 
A B 
23229  1 P 47,XX,+10,der(21)r(21)(q?)[10] 10 F 437 1 
19578  2 P 48,XY,+X,?t(6;20)(p1;q1),?t(7;9)(p1;p2), 
i(9)(q10),+12,der(21)(q?)[9] 
11 M 426  
21567 3 P 52,XX,+9,-12,-12,+7mar[cp4] 8 F 430 14 
23317 4 R 45,X,del(X)(q22),del(1)(p13),der(9;17)(q10;
q10),del(10)(q22),del(11)(q14), 
add(21)(q22)[4]/46,idem,+mar[4] 
17 F 439  
24259  5 P 46,XX,t(2;16)(p1?2;q2?3),-21,+mar[5] 13 F 447 7 
Samples which failed to engraft 
19578** 2 R Karyotype not available no RUNX1 
amplification 
11 M 426 45 
9028 6 P 46,X,add(X)(q26-q28),?7, 
der(21)dup(21)(q?)[8] 
10 F 511 28 
9864 7 P 47,XY,dup(21)(q?),+dup(21)(q?)[6] 10 M 512 18 
Supplementary Table 2. Karyotypes and demographic details of iAMP21-ALL with bone marrow 
trephines used for histological comparison with iAMP21-ALL derived xenografts. 
 
Age was at diagnosis. *Patients 1 and 5 were also used to create xenografts. †iAMP21 identified by 
interphase FISH. **Normal population excluded from abnormal karyotypes. N/A, not available. 
Previously published IDs refer to previous publications; A - Harrison et al 2014(12) B - Ryan et al 
2016(3). 
 
Supplementary Table 3. Karyotypes and demographic details of additional B-ALL patient samples 
used to create xenografts examined histologically. 
 
 
Age was at diagnosis. *iAMP21 identified by interphase FISH. † ETV6-RUNX1 fusion identified by FISH. ** 
Normal population excluded from abnormal karyotypes. N/A, not available. Previously published IDs 
refer to previous publications; A - Harrison et al 2014(12) B - Ryan et al 2016(3). 
  
 
Patient 
registration 
number  
 
ID this 
study 
 
Presentation (P) 
/relapse (R) 
 
Karyotype** 
 
Age 
(years) 
 
Sex 
 
Previously 
published patient 
ID 
A B 
23229*  1 P 47,XX,+10,der(21)r(21)(q?)[10] 10 F 437 1 
24259*  5 P 46,XX,t(2;16)(p1?2;q2?3),-21,+mar[5] 13 F 447 7 
5754 8 P 46,XY,ider(21)(q10)dup(21)(q?)[6] 9 M 478  
21795† 9 P 46,XX[20] 8 F   
23982 10 P 46,XX,add(21)(q2?2)[6] 8 F 444 21 
25821 11 P 46,XX,del(7)(q22),del(8)(q22),add(15)(q26), 
der(21)[cp10] 
25 F   
27421† 12 P N/A 14 F   
 
Patient 
registration 
number  
 
ID this 
study 
 
Genetic subtype 
/Presentation (P) or 
relapse (R) 
 
Karyotype** 
 
Age 
(years) 
 
Sex 
 
Previously 
published patient 
ID 
A B 
22322 12 iAMP21/P 46~47,XX,+?X,add(7)(p22),del(11)(q23),
del(13)(q12q14),dup(21)(q22),+r 
8 F 433 15 
20724* 13 iAMP21/P 46,XY 3 M 429 16 
23299 14 iAMP21/P 46,XY,der(1)t(1;13)(q2?5;q12),?del(9)(p
2?1),-11,-13,-15,del(16)(q10),-17,-
21,+3mar[5]/45,XY, 
rob(15;21)(q10;q10)?c[5] 
10 M 439 43 
22340 15 iAMP21/P 46,XX,ider(21)?inv dup(21)(q1q2)[9] 10 F 434 11 
24259* 5 iAMP21/R N/A 13  447 7 
10420† 16 ETV6-RUNX1/P 46,XY,del(6)(q13q23),add(8p),der(12) 
?t(12;22)(p?;q?),+21,-22,der(22)t(?;22) 
3 M   
2058 17 Hyperdiploid/P 52,XX,+X,+9,add(9)(p13),+14,+18,+21, 
+21 
4 F   
Supplementary Table 4. Details of xenograft generation and ex-vivo analysis of tumour load.  
Xenograft id 
/sex of host 
time to cull (weeks) 
spleen 
weight/tumour 
load** 
CD19 CD10 
+ve cells Bone 
marrow 
+ve cells 
Spleen 
Patient 1; CD19 92%, CD10 94%, CD34 93%. 
primary mice; 1.6x106 cells transplanted / mouse 
1°1a/M 38 1.13g/NA +ve  +ve 40% 36% 
1°1b/M 30 1.43g/NA +ve +ve 60% 23% 
secondary mice; 2x104 1°1B  bone marrow  cells transplant / mouse  
2°1a/F 35 0.8g/6x108 +ve +ve 50% 32% 
2°1b/F 24 0.33g/NA +ve +ve 42% 33% 
tertiary mice; 2x106 2°1A spleen cells transplanted / mouse 
3°1a/F 22 1.77g/8.9x108 +ve +ve Ficol  90% Ficol 95% 
3°1b/F 23 1.6g/1.4x109 +ve +ve Ficol  98% Ficol 95% 
3°1c/M 28 enlarged*/3.7x108 +ve +ve NA Ficol  96% 
3°1d/M 28 enlarged*/1.8x108 +ve +ve NA Ficol  94% 
3°1e/M 27 1.6g/8x108 +ve +ve 92% Ficol  95% 
3°1f/M 27 1.78g/1.5x109 +ve +ve NA Ficol 96% 
3°1g/M 12 0.66g/2.5x109 +ve +ve 71% Ficol 99% 
Patient 2; CD19 85%, CD10 83%, CD34 80% 
primary mouse 3.3x105 transplanted 
1°2a/NA 29 0.285g/NA +ve +ve 40% 27% 
secondary mice; 1x106 1°2A spleen cells transplanted / mouse  
2°2a/F 8 0.34g/NA +ve +ve 6% 5% 
2°2b/F 22 0.73g/2.4x108 +ve +ve 18% Ficol 85% 
2°2c/F 22 1.3g/1x109 +ve +ve NA NA 
2°2d/F 29 1.0g/1.4x109 +ve +ve NA Ficol 97% 
2°2e/F 29 1.5g/6x108 +ve +ve NA NA 
2°2f/F 23 1.2g/1.5x109 +ve +ve 51% Ficol 80% 
2°2g/M 25 1.3g/2.5x108 +ve +ve 48% Ficol 85% 
Patient 3; CD19 85%, CD10, 84%, CD34 83% 
primary mice; 1x106 cells transplanted / mouse 
1°3a/F 25 enlarged*/NA +ve +ve 21% Ficol 87% 
1°3b/F 35 3.6g/4x109 +ve +ve NA Ficol 99% 
Secondary mice; 1x106 1°3B spleen cells transplanted / mouse. 
2°3a/M 16 2.53g/4x109 +ve +ve 38% Ficol 92% 
2°3b/M 16 0.28g/3.6x106 +ve +ve 29% Ficol 97% 
2°3c/M 15 2.4g/7x108 +ve +ve 36% Ficol 95% 
2°3d/M 16 3.6g/3.22x109 +ve +ve 34% Ficol 95% 
2°3e/M 16 1.3g/6x108 +ve +ve 32% Ficol 95% 
Patient 4; NA 
Primary mice; 2x105 cells transplanted / mouse. 
1°4a/F 22 enlarged*/NA +ve +ve NA Ficol 95% 
1°4b/F 20 1.3g/1.4x109 +ve +ve NA Ficol 97% 
1°4c/F 20 1.3g/9.7x108 +ve +ve 95% Ficol 96% 
Patient 5; CD19 56%, CD10 59%, CD34 62%. 
Primary mouse; 1x106 cells transplanted. 
1°5a/F 53 0.80g/6x108 +ve +ve NA Ficol 80% 
Transduced with pSLIEW and analysed by in-vivo imaging and histology post-mortem  
Patient 1; 1.5x106 transduced 3°1E spleen cells transplanted / mouse 
1aSLIEW /F 
 
16 0.53g/NA +ve NA NA Ficol 92% 
1bSLIEW /F 
 
18 0.88g/NA +ve NA NA Ficol 92% 
Patient 2; 1.5x106 transduced 2°2E spleen cells transplanted / mouse 
2aSLIEW /F 
 
16 0.40g/NA +ve NA NA Ficol 86% 
2bSLIEW /F 
 
14 0.55g/2x108 +ve NA NA Ficol 89% 
Patient 3; 1.5x106 transduced 2°3D spleen cells transplanted / mouse 
3aSLIEW /F 
 
15 0.23g/NA +ve NA NA Ficol 85% 
3bSLIEW /F 
 
15 0.27g/NA +ve NA NA Ficol 94% 
Patient 4; 1.5x106 transduced 1°4B spleen cells transplanted / mouse 
4aSLIEW /F 
 
15 0.83g/NA +ve NA NA Ficol 89% 
4bSLIEW /F 
 
14 0.81g/NA +ve NA NA Ficol 79% 
Ficol indicates that the sample was purified by Ficol gradient separation. * Spleen weight not 
recorded but splenomegaly noted. ** Tumour load refers to the total number of cells isolated (a 
variable proportion of cells are lost in the course of purification over Ficol). NA data not available. 
  
Supplementary table 5. Xenograft Immunophenotypic data.  
id  
%CD19+ve (MFI) %CD10+ve (MFI) %CD34+ve (MFI) %CD38+ve (MFI) 
BM spleen BM spleen BM spleen BM spleen 
Patient 1; CD19 92%, CD10 94%, CD34 93%. 
primary mice 
1°1a 100 (10920) 100 (11171) 100 (21462) 100 (18458) 52 (5224) 51 (4623) 18 (567) 10 (474) 
1°1b 100 (10133) 100 (12845) 99 (9642) 100 (53563) 44 (2940) 78 (12640) 3 (340) 50 (1579) 
secondary mice 
2°1a 100 (28751) 100 100 (61831) 100 100 (19668)  97 (4334)  
2°1b 100 (21717) 100 (24860) 100 (59035) 100 (80485) 96 (17696) 97 (20089) 88 (3028) 91 (3234) 
tertiary mice 
3°1a 100 100 (21614) 100 100 (51772)  90 (14720)  93 (4281) 
3°1b 100 100 (16847) 100 100 (42753)  70 (11325)  72 (3170) 
3°1c  100 (18589)  100 (43906)  82 (11666)  82 (3113) 
3°1d  100 (16382)  100 (46420)  72 (12212)  75 (3170) 
3°1e 100 100 (17125) 100 100 (45972)  69 (11586)  73 (3132) 
3°1f  100 (19948)  100 (48138)  77 (12268)  83 (3095) 
3°1g 100 (24742) 100 (15819) 100 (68666) 100 (46872) 94 (17696) 89 (12815) 97 (4831) 94 (3847) 
Patient 2; CD19 85%, CD10 83%, CD34 80% 
primary mouse  
1°2a 100 100 100 100     
secondary mice 
2°2a 100 (14349) 100 (12815) 100  (51397) 100 (38352) 82 (15065) 84 (12296) 85 (3089) 63 (1881) 
2°2b 100  100 (10341) 100  100 (38723)  89 (11020)  39 (1204) 
2°2c  100   100      
2°2d  100 (8262)  100 (36547)  88 (10341)  16 (762) 
2°2e 100 (9664) 100 (7629) 100 (45750) 100 (30305) 91 (14283) 89 (9513) 29 (1125) 1 (700) 
2°2f 100 (11171) 100 (12101) 100 (61831) 100 (54881) 93 (17490) 92 (14652) 55 (1902) 51 (1652) 
2°2g 100 100 100 100     
Patient 3; CD19 85%, CD10, 84%, CD34 83% 
primary mice 
1°3a 100 100 100 100     
1°3b  100  100     
Secondary mice 
2°3a 100 (21110) 100 (26956) 100(143642) 100(124849) 84 (29236) 81 (26384) 19 (1784) 6 (1320) 
2°3b 100 100 (22448) 100 100(130499)  56 (25038)  1 (1188) 
2°3c 100 100 (20137) 100 100(127329)  82 (27739)  3 (1290) 
2°3d 100 100 (24161) 100 100(130499)  78 (25038)  3 (1188) 
2°3e 100 100 (19807) 100 100(120329)  66 (24334)  1 (1127) 
Patient 4;  
Primary mice 
1°4a  100 (17367)  100 (30743)  60 (7817)  19 (807) 
1°4b  100 (17820)  100 (54747)  80 (18853)  66 (2428) 
1°4c 100 100 (18941) 100 100 (37984)  35 (8027)  88 (3532) 
Patient 5; CD19 56%, CD10 59%, CD34 62%. 
Primary mouse 
1°5a 100 100 100 100     
Transduced with pSLIEW and analysed by in-vivo imaging and histology post-mortem  
Patient 1 
1aSLIEW  
 
 100  100     
1bSLIEW  
 
 100 (16926)  100 (57616)  71 (13235)  86 (3400) 
Patient 2 
2aSLIEW  
 
 100  100     
2bSLIEW  
 
 100  100     
Patient 3 
3aSLIEW  
 
 100 (18720)  100(145780)  48 (27345)  0 (1744) 
3bSLIEW  
 
 100  100     
Patient 4 
4aSLIEW  
 
 100 (15709)  100 (36635)  58 (9156)  77 (3046) 
4bSLIEW  
 
 100  100     
 
Mean fluorescence intensity (MFI). Gray boxes indicate that no sample was available for analysis.  
 Supplementary table 6. Bone marrow histology of additional xenografts. 
*WT (wild type morphology similar to control NSG mice), A and B (as defined in the main text and 
shown in figures 2, and Supplementary figures 3 and 7).  
 
  
Xenograft ID Genetic sub-type Sample Morphology type* 
1°5Ra iAMP21 femur/sternum A 
1°5Rb iAMP21 femur/sternum A/B 
1°13a iAMP21 tibia A 
1°13b iAMP21 tibia/sternum A 
1°14a iAMP21 tibia/sternum A 
1°14b iAMP21 tibia/sternum A 
1°14c iAMP21 tibia A 
1°15a iAMP21 tibia/sternum WT/A 
1°15b iAMP21 tibia/sternum A 
1°16a iAMP21 humerus/sternum WT/A 
1°16b iAMP21 humerus/sternum WT/A 
2°17a ETV6-RUNX1 tibia A 
1°18a Hyperdiploid forelimb/sternum A/B 
Supplementary Table 7. Copy number abnormalities (CNA) identified by SNP6.0 array analysis in 
patients and xenografts. 
                                                                                                                                   Y; clonal CNA present  
                                                                                                                                   N; CNA not detected 
                                                                                                                                   S; sub-clonal CNA present  
  
                          Patient 1 concordant CNA 
    
1° 2° 3° Xenografts 
 
Chr  abnormality genomic position patient a b a b a b c d e f g genes  
4 del (CN 1) 153060000-153272000 Y Y Y Y Y Y Y Y Y Y Y Y FBXW7 
6 del (CN 1) 25950000-26285000 Y Y Y Y Y Y Y Y Y Y Y Y 33 genes TRIM38, HIST1H1A- HIST1H2B1  
6 del (CN 0) 26135000-26255000 Y Y Y Y Y Y Y Y Y Y Y Y 18 genes HIST1H1E- HIST1H2B1  
7 del (CN 1) 49850000-51565000 Y Y Y Y Y Y Y Y Y Y Y Y VWC2, ZPBP, C7orf72, IKZF1, FIGNL1, DDC, GRB10, COBL 
7 del (CN 1) 65800000-66475000 Y Y Y Y Y Y Y Y Y Y Y Y 9 gene TPST1-TYW1 
7 del (CN 1) 137889000-138447000 Y Y Y Y Y Y Y Y Y Y Y Y TRIM24, SVOPL, ATP6VOA4 
7 del (CN 1) 138489000-141624000 Y Y Y Y Y Y Y Y Y Y Y Y 30 genes KIAA1549- OR9A4,  
7 del (CN 1) 142060000-142202000 Y Y Y Y Y Y Y Y Y Y Y Y none 
7 del (CN 1) 154559000-155465000 Y Y Y Y Y Y Y Y Y Y Y Y 9 genes DPP6-RBM33 
8 del (CN 1) 60030000-60446000 Y Y Y Y Y Y Y Y Y Y Y Y TOX 
12 del (CN 1) 11825000-12025000 Y Y Y Y Y Y Y Y Y Y Y Y ETV6 (exons 1-5), RNU6-19 (Exons1&2) 
12 del (CN 1) 121160000-121274000 Y Y Y Y Y Y Y Y Y Y Y Y UNC119B, MIR4700, ACADS, SPPL3 
13 del (CN 1) 48984700-49074000 Y Y Y Y Y Y Y Y Y Y Y Y RB1 (ex ?17-end), LPAR6, RCBTB2 (ex 1-3) 
15 del(CN 1) 93158000-94982000 Y Y Y Y Y Y Y Y Y Y Y Y FAM174B, ASB9P1, LOC100507217, CHD2, RGMA, MCTP2 
 
Patient 1 discordant CNA 
3 del (CN 1) 32375000-32552000 N N N Y N Y Y Y Y Y Y Y CMTM 8, 7, 6 
9 del (CN 1) 19540000-32310000 N N N Y N Y Y Y Y Y Y Y 40 genes SLC24A2- MOB3B, 
9 del (CN 0) 19620000-27194000 N N N Y N Y Y Y Y Y Y Y 37 genes SLC24A2, MLLT3-TEK 
10 trisomy 
 
Y N N N N N N N N N N N 
 
   
Patient 2 concordant CNA 
    
2° xenografts 
  
Chr Abnormality genome position patient a b c d e f genes 
3 del (CN 1) 35528000-35684000 Y Y Y Y Y Y Y ARPP21 (exons1&2) 
6 del (CN 1) 46699000-47018000 Y Y Y Y Y Y Y PLA2G7, LOC100287718, MEP1A, GPR116, GPR110 
7 del (CN 1) 50150000-51210000 Y Y Y Y Y Y Y C7orf72, IKZF1, FIGNL1, DDC, GRB10, COBL 
7 del (CN 1) 109732000-158646480 Y Y Y Y Y Y Y many 
8 del (CN 1) 53567000-53596000 Y Y Y Y Y Y Y RB1CC1 (exons 9-20) 
9 del (CN 1) 0-39500000 Y Y Y Y Y Y Y many 
9 del (CN 0) 20365000-22404000 Y Y Y Y Y Y Y 32 genes MLLT3-CDKN2B-AS1 
9 amp (CN 3) 70950000-141067840  Y Y Y Y Y Y Y many 
11 del (CN 1) 63950000-64000000 Y Y Y Y Y Y Y STIP1, FERMT3, TRPT1, NUDT22, DNAJC4, VEGFB 
12 del (CN 1) 11846000-11930000 Y Y Y Y Y Y Y ETV6 (ex 2) 
13 amp (CN 3) 67315000-115150780 Y Y Y Y Y Y Y many 
16 del (CN 1) 3781000-3824000 Y Y Y Y Y Y Y CREBBP (ex 1-19) 
20 del (CN 1) 56168000-56690000 Y Y Y Y Y Y Y ZBP1, PMEPA1, MIR4532 
22 del (CN 1) 22320000-22540000 Y Y Y Y Y Y Y TOP3B 
X WCG 
 
Y Y Y Y Y Y Y 
 
 
Patient 2 discordant CNA 
2 del (CN 1) 74000000-86000000 N N N S N N N Many TPRKB-ST3GAL5 
12 trisomy 
 
Y N N N N N N 
 
X iso(p) 
 
N N N S Y N N many 
X del (CN 1) 47248000-47342000 N N Y S S S S ZNF157, ZNF41 
 
 
Patient 3 concordant CNA 
    
1° 2° xenografts 
 
Chr  Abnormality genomic position patient a b a b c d e genes 
4 amp (CN 3) 70125000-70238000 Y Y Y Y Y Y Y Y UGT2B28 
5 trisomy  Y Y Y Y Y Y Y Y  
10 trisomy  Y Y Y Y Y Y Y Y  
12 del (CN 1) 104860000-105042000 Y Y Y Y Y Y Y Y CHST11 (ex 2&3) 
14 trisomy  Y Y Y Y Y Y Y Y  
17 trisomy  Y Y Y Y Y Y Y Y  
17 del (CN 1) 62590000-62665000 Y Y Y Y Y Y Y Y SMURF2 (ex 15-18) 
X del (CN 1) 1380000-1604000 Y Y Y Y Y Y Y Y CSF2RA, IL3RA, SLC25A6, ASMTL-AS1, ASMTL, P2RY8(UTR). 
 
Patient 3 discordant CNA 
9 trisomy  Y Y N N N N N N  
12 del (CN 1) 0-24500000 S S N N N N N N 
 
12 del (CN 1) 11950000-32460000 N N S N N N N N ETV6 (ex 3-7)  many genes BICD1 (exon 1-4) 
X trisomy  Y S Y Y S Y S S  
 
 
 
  
patient 4 concordant CNA 
   
1° xenografts 
 
Chr Abnormality genomic position 1 2 genes in region 
1 complex 89800000-121500000 Y Y many 
1 del (CN 0) 152550000-152590000 Y Y LCE3, LCE3B, LCE3A 
1 del (CN 1) 196720000-196800000 Y Y CFHR3, CFHR1 
2 del (CN 1) 184500000-184600000 Y Y ZNF804A 
5 del (CN 1) 142674000-142750000 Y y NR3C1 
5 del (CN 0) 142674000-142724350 Y y NR3C1 
9 del (CN 1) 0-34150000 Y y many including CDKN1A/B 
9 del (CN 0) 21954000-22119000 y y CDKN1A, CDKN1B, CDKN1B-AS1 
9 del (CN 1) 37000000-37350000 Y Y PAX5, ZCCHC7   
10 del (CN 0) 98350000-98700000 Y Y PIK3AP1, LCOR 
11 del (CN1) 82000000-134963460 Y Y many 
12 del (CN 1) 11800000-12000000 Y Y ETV6 intragenic 
12 del (CN 0) 111760000-112060000 Y Y CUX2, FAM109A, SH2B3, ATXN2 
12 del (CN 1) 133350000-133800000 Y Y COLGA3, CHFR, ZNF605, ZNF26, ZNF84, ZNF140, ZNF10, ZNF268, ANHX 
13 del (CN 1) 44600000-45050000 Y Y SERP2 
20 del (CN 1) 1500000-1630000 Y Y SIRPD, SIRPB1, SIRPG 
 
Patient 4 discordant CNA 
4 del (CN 1) 174060000-174260000 Y N GALNT7, HMGB2    
4 amp (CN2) 69350000-69500000 N Y UGT2B17 
10 del (CN 1) 90000000-135534000 Y Y many  
10 del (CN 1)) 80800000-126400000 N N many 
10 del (CN 0) 98015000-98060000 N Y BLNK  
14 amp (CN 3) 36900000-43900000 Y N 13 genes SLC25A21- LRFN5 
14 del (CN 1) 43900000-107349520 Y N many  
16 del (CN 1) 3770000-3920000 Y N CREBBP 
17 amp (CN 1) 25300000-27450000 N N many 
17 amp (CN 2) 25920000-26300000 Y Y many 
17 amp (CN 1) 25300000-25920000 Y Y many 
22 del (CN 1) 37630000-37740000 N N RAC2, CYTH4 
Patient 5 concordant CNA 
   
patient 1° xenograft 
Chr Abnormality genomic position presentation 
 
relapse 
 
a genes 
2 del (CN 1) 63776000-75095000 y Y Y many 
4 del (CN 1) 71760000-71900000 y Y Y MOB1B, DCK 
6 del (CN 1) 26126000-26260000 y Y Y 16 genes HIST1H1E- HIST1H2BH 
 
Patient 5 discordant CNA 
1 del (CN 1) 234612000-235540000 N N S 8 genes TARBP1- ARID4B,  
2 del (CN 1) 2322000-8874000 S N Y LOC100506274, LOC339788, LINC00299, ID2, 
KIDINS220 (ex 1) 
3 del (CN 1) 114080000-114680000 S N Y ZBTB20 
3 del (CN 1) 45900000-48250000 S Y N 37 genes CCR9-CAMP 
5 del (CN 1) 158088000-158149000 N N S EBF1 exons 1-5 
5 del (CN 1) 158380000-158580000 N Y N EBF1 exons 10-16 
12 CN-LOH 53500000-133721800 Y Y N many 
12 del (CN 1) 111050000-112135000 S N Y 12 genes TCTN1- ACAD10 
Supplementary Table 8. Regions of chromosome 21 copy number change that occurred in 
xenografts from patient 1. 
  
start  end size 
CN 
change 
0 16446092 16446092 0 
16446092 17302313 856221 1 
17381183 17697572 316389 -2 
17697723 18163458 465735 -1 
18163544 18174691 11147 0 
18177172 20521089 2343917 -1 
20521648 21760268 1238620 0 
21760283 22125481 365198 -2 
22125690 22517120 391430 0 
22517189 23343710 826521 -2 
23345771 26533474 3187703 0 
26533786 28305871 1772085 -1 
28306308 29236061 929753 -2 
29243377 31443709 2200332 -1 
31447334 31680485 233151 0 
31683535 33949423 2265888 -1 
33949543 48096945 14147402 0 
 
Supplementary Table 9. MLPA values for patients and their xenografts. A score of 1 indicates 
normal copy number. Examples with clear evidence for CN changes between samples are highlighted 
(loss by shades of red and gain by shades of green). 
  Patient 1 
 patient    xenografts 
Target  2°1b 3°1g 
    
01a_EBF1_ex16 1.035 0.855 1.142 
01b_EBF1_ex14 1.086 1.114 0.952 
01c_EBF1_ex10 1 0.974 1.16 
01d_EBF1_ex1 0.965 0.958 1.127 
02a_IKZF1_ex1 0.588 0.499 0.596 
02b_IKZF1_ex2 0.649 0.481 0.56 
02c_IKZF1_ex3 0.616 0.451 0.598 
02d_IKZF1_ex4 0.583 0.454 0.603 
02e_IKZF1_ex5 0.639 0.435 0.567 
02f_IKZF1_ex6 0.609 0.566 0.529 
02g_IKZF1_ex7 0.636 0.511 0.597 
02h_IKZF1_ex8 0.55 0.49 0.622 
03a_JAK2_ex23  0.844 0.825 
03b_CDKN2A_ex5 0.936 0.987 0 
03c_CDKN2A_ex2a 1.022 0.897 0 
03d_CDKN2B_ex2 1.021 0.919 0 
04a_PAX5_ex10 1.032 0.97 1.255 
04b_PAX5_ex8 0.942 0.828 1.236 
04c_PAX5_ex7  0.966 0.994 
04d_PAX5_ex6 1.015 0.974 1.183 
04e_PAX5_ex5 0.981 1.086 0.996 
04f_PAX5_ex2 1.149 0.795 1.171 
04g_PAX5_ex1 0.981 0.938 1.149 
05a_ETV6_ex1A 0.97 1.048 0.969 
05b_ETV6_ex1B 1.003 1.1 0.948 
05c_ETV6_ex2 0.201 0 0.527 
05d_ETV6_ex3 0.401 0.511 0.473 
05e_ETV6_ex5 0.616 9 0.627 
05f_ETV6_ex8 0.986 0.945 1.122 
06a_BTG1-AREA1 0.972 0.913 1.043 
06b_BTG1_AREA2 0.893 0.919 1.106 
06c_BTG1_ex2 1.038 0.967 1.14 
06d_BTG1_ex1 1.06 0.815 1.262 
07a_RB1_ex6 0.955 0.874 1.137 
07b_RB1_ex14 1.015 94 0.967 
07c_RB1_ex19 0.117 0 0 
07d_RB1_ex24 0.118 0 0 
07e_RB1_ex26 0.095 0 0 
08a_SHOX_area 1.01 0.918 0.995 
08b_CRLF2_ex4 0.997 0.942 1.09 
08c_CSF2RA_ex10 1.043 0.993 0.924 
08d_IL3RA_ex1 0.98 1.038 0.852 
08e_P2RY8_ex2 0.987 0.943 1.106 
08f_ZFY_ex4 0 -1 -1 
 
  Patient 2 
 patient secondary xenografts 
Target  2°2c 2°2d 2°2b 2°2e 2°2f 
       
01a_EBF1_ex16 0.975 0.965 0.918 0.945 1.054 1.019 
01b_EBF1_ex14 0.948 0.949 1.025 0.953 0.84 0.901 
01c_EBF1_ex10 0.965 0.994 1.06 1.061 1.083 1.083 
01d_EBF1_ex1 0.898 1.051 1.067 0.998 1.157 1.078 
02a_IKZF1_ex1 0.485 0.541 0.602 0.579 0.538 0.551 
02b_IKZF1_ex2 0.539 0.53 0.583 0.536 0.572 0.543 
02c_IKZF1_ex3 0.547 0.535 0.541 0.555 0.579 0.579 
02d_IKZF1_ex4 0.55 0.539 0.599 0.59 0.598 0.622 
02e_IKZF1_ex5 0.544 0.534 0.544 0.526 0.574 0.559 
02f_IKZF1_ex6 0.575 0.494 0.497 0.494 0.447 0.53 
02g_IKZF1_ex7 0.483 0.599 0.665 0.598 0.61 0.588 
02h_IKZF1_ex8 0.509 0.611 0.648 0.602 0.645 0.635 
03a_JAK2_ex23 0.565 0.426 0.432 0.409 0.368 0.396 
03b_CDKN2A_ex5 0 0 0 0 0 0 
03c_CDKN2A_ex2a 0 0 0 0 0 0 
03d_CDKN2B_ex2 0 0 0 0 0 0 
04a_PAX5_ex10 0.512 0.591 0.622 0.587 0.669 0.625 
04b_PAX5_ex8 0.5 0.732 0.823 0.862 0.703 0.637 
04c_PAX5_ex7 0.552 0.659 0.72 0.677 0.497 0.482 
04d_PAX5_ex6 0.512 0.592 0.662 0.633 0.629 0.653 
04e_PAX5_ex5 0.56 0.545 0.593 0.54 0.451 0.491 
04f_PAX5_ex2 0.508 0.548 0.616 0.647 0.605 0.591 
04g_PAX5_ex1 0.516 0.556 0.595 0.639 0.624 0.632 
05a_ETV6_ex1A 1.344 1.016 1.047 1.027 0.942 0.919 
05b_ETV6_ex1B 1.307 0.939 0.948 0.97 0.875 0.891 
05c_ETV6_ex2 0.596 0.522 0.532 0.506 0.456 0.476 
05d_ETV6_ex3 1.378 0.915 0.921 0.89 0.856 0.924 
05e_ETV6_ex5 1.39 1.069 1.047 1.076 1.146 1.123 
05f_ETV6_ex8 1.283 1.07 1.074 1.068 1.126 1.101 
06a_BTG1-AREA1 1.215 0.945 0.973 0.924 0.997 0.95 
06b_BTG1_AREA2 1.247 1.02 1.039 1.021 1.043 1.04 
06c_BTG1_ex2 1.258 1.078 1.093 1.033 1.138 1.104 
06d_BTG1_ex1 1.141 1.229 1.391 1.395 1.256 1.307 
07a_RB1_ex6 0.909 1.013 1.06 0.991 1.087 1.077 
07b_RB1_ex14 0.984 0.962 0.998 0.939 0.894 0.924 
07c_RB1_ex19 0.93 1.031 1.094 1.012 0.919 0.926 
07d_RB1_ex24 1.004 1.048 1.023 1.029 0.85 0.955 
07e_RB1_ex26 0.998 0.954 0.876 0.88 0.83 0.877 
08a_SHOX_area 1.404 1.315 1.26 1.332 1.651 1.347 
08b_CRLF2_ex4 1.446 1.34 1.486 1.343 1.46 1.536 
08c_CSF2RA_ex10 1.496 1.268 1.205 1.111 1.351 1.221 
08d_IL3RA_ex1 1.353 1.384 1.506 1.433 1.328 1.232 
08e_P2RY8_ex2 1.252 1.52 1.717 1.657 1.893 1.637 
08f_ZFY_ex4 1000 1000 1000 1000 1000 1000 
 
 
 
 
                                         Patient 3 
 Patient   xenografts  
Target  1°3b 2°3c 2°3a 2°3e 2°3b 2°3d 
        
01a_EBF1_ex16 1.356 1.432 1.506 1.529 1.449 1.553 1.507 
01b_EBF1_ex14 1.306 1.403 1.319 1.298 1.323 1.319 1.423 
01c_EBF1_ex10 1.405 1.223 1.571 1.596 1.522 1.621 1.512 
01d_EBF1_ex1 1.363 1.511 1.521 1.621 1.574 1.56 1.429 
02a_IKZF1_ex1 1.01 1.047 1.051 1.059 1.041 1.038 0.987 
02b_IKZF1_ex2 0.964 0.969 1.022 1.083 1.051 1.037 0.999 
02c_IKZF1_ex3 0.978 1.042 1.053 1.09 1.096 1.089 1.063 
02d_IKZF1_ex4 0.949 1.033 1.034 1.17 1.098 1.14 1.066 
02e_IKZF1_ex5 1 0.95 1.019 1.063 1.054 1.048 0.994 
02f_IKZF1_ex6 1.109 0.901 0.891 0.915 0.916 0.994 1.018 
02g_IKZF1_ex7 0.941 1.198 1.143 1.164 1.168 1.102 1.077 
02h_IKZF1_ex8 1.037 1.183 1.153 1.239 1.213 1.185 1.094 
03a_JAK2_ex23  0.722 0.652 0.676 0.719 0.783 0.836 
03b_CDKN2A_ex5 1.227 1.011 1.054 1.154 1.116 1.104 1.009 
03c_CDKN2A_ex2a 1.348 1.171 1.018 1.037 1.033 1.022 0.964 
03d_CDKN2B_ex2 1.215 1.128 1.076 1.142 1.116 1.074 1.034 
04a_PAX5_ex10 1.096 1.275 1.214 1.239 1.185 1.164 1.121 
04b_PAX5_ex8 1.334 1.676 1.42 1.156 1.213 1.138 1.242 
04c_PAX5_ex7  1.391 1.084 0.848 0.919 0.909 1.095 
04d_PAX5_ex6 1.231 0.938 0.983 1.189 1.162 1.19 1.113 
04e_PAX5_ex5 1.309 0.798 0.729 0.913 0.97 0.923 0.973 
04f_PAX5_ex2 1.213 1.063 1.008 1.106 1.105 1.158 1.05 
04g_PAX5_ex1 1.207 1.06 1.089 1.145 1.077 1.136 1.046 
05a_ETV6_ex1A 0.838 1.009 0.912 0.85 0.915 0.91 0.939 
05b_ETV6_ex1B 0.843 0.926 0.882 0.826 0.855 0.877 0.875 
05c_ETV6_ex2 0.856 1.001 0.942 0.868 0.883 0.909 0.944 
05d_ETV6_ex3 0.868 0.541 0.737 0.758 0.791 0.792 0.864 
05e_ETV6_ex5 0.86 0.709 1.106 1.017 1.083 1.02 1.04 
05f_ETV6_ex8 0.85 0.68 1.028 0.964 1.008 1.007 0.974 
06a_BTG1-AREA1 1.003 0.933 0.941 0.95 0.948 0.977 0.922 
06b_BTG1_AREA2 1.136 1.031 0.989 1.013 0.988 1.064 0.976 
06c_BTG1_ex2 0.91 1.085 1.098 1.081 1.065 1.132 1.045 
06d_BTG1_ex1 0.953 1.322 1.114 1.295 1.231 1.304 1.086 
07a_RB1_ex6 1.079 1.013 1.026 1.093 0.992 1.049 0.985 
07b_RB1_ex14 0.998 0.938 0.871 0.817 0.841 0.863 0.917 
07c_RB1_ex19 0.875 1.016 0.929 0.914 0.911 0.922 0.962 
07d_RB1_ex24 0.926 0.987 0.918 0.953 0.91 0.954 0.978 
07e_RB1_ex26 0.933 0.885 0.855 0.884 0.835 0.913 0.958 
08a_SHOX_area 1.305 1.204 1.202 1.374 1.186 1.18 1.279 
08b_CRLF2_ex4 1.325 1.191 1.445 1.454 1.209 1.239 1.437 
08c_CSF2RA_ex10 0.579 0.451 0.35 0.379 0.216 0.195 0.408 
08d_IL3RA_ex1 0.583 0.412 0.301 0.377 0.24 0.199 0.402 
08e_P2RY8_ex2  0.562 0.453 0.514 0.282 0.237 0.441 
08f_ZFY_ex4  -1 -1 -1 -1 -1 -1 
  
  Patient 5   
 patient 
primary 
xenograft 
Target  1°5a 
   
01a_EBF1_ex16 0.777 0.536 
01b_EBF1_ex14 0.771 0.554 
01c_EBF1_ex10 0.928 1.006 
01d_EBF1_ex1 0.865 0.988 
02a_IKZF1_ex1 0.97 1.025 
02b_IKZF1_ex2 1.005 1.004 
02c_IKZF1_ex3 0.956 1.003 
02d_IKZF1_ex4 0.966 1.028 
02e_IKZF1_ex5 1 1.011 
02f_IKZF1_ex6 1.09 0.994 
02g_IKZF1_ex7 0.905 0.975 
02h_IKZF1_ex8 0.964 1.013 
03a_JAK2_ex23  0.976 
03b_CDKN2A_ex5 0.998 0.564 
03c_CDKN2A_ex2a 1.004 0.542 
03d_CDKN2B_ex2 1.017 0.979 
04a_PAX5_ex10 0.904 1.032 
04b_PAX5_ex8 0.971 0.93 
04c_PAX5_ex7 1.143 0.948 
04d_PAX5_ex6 0.98 1.05 
04e_PAX5_ex5 1.013 1.018 
04f_PAX5_ex2 1 1.062 
04g_PAX5_ex1 0.988 1.042 
05a_ETV6_ex1A 1.025 0.995 
05b_ETV6_ex1B 1 1.002 
05c_ETV6_ex2 1.019 1.014 
05d_ETV6_ex3 1 1.035 
05e_ETV6_ex5 1 1.033 
05f_ETV6_ex8 0.991 1.02 
06a_BTG1-AREA1 1.022 0.986 
06b_BTG1_AREA2 1.031 0.938 
06c_BTG1_ex2 0.983 1.001 
06d_BTG1_ex1 1.011 0.995 
07a_RB1_ex6 1.022 1.022 
07b_RB1_ex14 1.039 1.031 
07c_RB1_ex19 1.01 0.906 
07d_RB1_ex24 1.2 0.949 
07e_RB1_ex26 0.982 0.914 
08a_SHOX_area 0.984 1.019 
08b_CRLF2_ex4 1.038 1.041 
08c_CSF2RA_ex10 1.008 1.018 
08d_IL3RA_ex1 1 1.031 
08e_P2RY8_ex2 0.979 1.04 
08f_ZFY_ex4 0 -1 
 
 
 
References for supplementary methods. 
 
1. Bomken S, Buechler L, Rehe K, et al. Lentiviral marking of patient-derived acute 
lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia. 
2013;27(3):718-721. 
2. Williams MT, Yousafzai YM, Elder A, et al. The ability to cross the blood-cerebrospinal fluid 
barrier is a generic property of acute lymphoblastic leukemia blasts. Blood. 2016;127(16):1998-2006. 
3. Ryan SL, Matheson E, Grossmann V, et al. The role of the RAS pathway in iAMP21-ALL. 
Leukemia. 2016; 30:1824-1831. 
4. Conway T, Wazny J, Bromage A, et al. Xenome--a tool for classifying reads from xenograft 
samples. Bioinformatics. 2012;28(12):i172-178. 
5. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. 
Bioinformatics. 2009;25(14):1754-1760. 
6. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. 
Bioinformatics. 2010;26(5):589-595. 
7. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in 
impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213-219. 
8. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping 
using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491-498. 
9. Van der Auwera GA, Carneiro MO, Levy-Moonshine A, et al. From FastQ data to high 
confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc 
Bioinformatics. 2013;43:11.10. 1-33. 
10. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences 
of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 
2010;26(16):2069-70. 
11. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat 
Biotechnol. 2011;29(1):24-6. 
12. Harrison CJ, Moorman AV, Schwab C, et al. An international study of intrachromosomal 
amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia. 
2014;28(5): 1015-1021. 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
  
 
